Efficacy and Safety of Envafolimab Combined With Doxorubicin and Ifosfamide as First-line Treatment for Advanced Soft Tissue Sarcoma is a PHASE2 clinical asset sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University in Soft Tissue Sarcoma. SEO and diligence focus: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.